Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

NCT06040320 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Post-transplant Lymphoproliferative Disorder

Interventions

DRUG: Polatuzumab vedotin
DRUG: Rituximab
DRUG: CHP

Sponsor

Washington University School of Medicine